Suppr超能文献

重症监护病房中2019冠状病毒病(COVID-19)患者的临床特征及死亡决定因素——一项回顾性探索性1年全人群研究

Clinical characteristics and determinants of mortality in coronavirus disease 2019 (COVID-19) patients on an intensive care unit-a retrospective explorative 1-year all-comers study.

作者信息

Brücker Wiebke, Mahabadi Amir Abbas, Hüschen Annette, Becker Jan, Daehnke Sebastian, Möhlenkamp Stefan

机构信息

Clinic of Cardiology and Intensive Care Medicine, Bethanien Krankenhaus Moers, Moers, Germany.

Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, University Medicine Essen, Essen, Germany.

出版信息

J Thorac Dis. 2022 May;14(5):1319-1331. doi: 10.21037/jtd-21-1713.

Abstract

BACKGROUND

Clinical outcome in patients with coronavirus disease 2019 (COVID-19) requiring treatment on intensive care units (ICU) remains unfavourable. The aim of this retrospective study was to exploratively identify potential predictors of unfavourable outcome in ICU patients diagnosed with COVID-19.

METHODS

In all patients with COVID-19 (n=50) or severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) as comorbidity (n=11) at our ICU we assessed clinical, respiratory and laboratory parameters with a potential role for outcome. Main outcome variables were intubation and mortality rates.

RESULTS

Between March 2020 and March 2021, 573 patients were hospitalized with SARS-CoV-2 infection. Of these, 61 patients (10.6%, 44.3% women) aged 66.4±13.3 were admitted to ICU. A proportion of 73.8% of patients had moderate or severe acute respiratory distress syndrome (ARDS). COVID-19 patients differed clinically from those with SARS-CoV-2 as comorbidity, such as severe heart or renal failure or sepsis as the leading cause of ICU admission, despite similar mortality rates (44.0% 45.5%, P>0.5). Among COVID-19 patients, those who died had more often severe ARDS (91% 46%, P=0.001), longer non-invasive ventilation (NIV) therapy prior to ICU (6.3±5.9 2.5±2.0 days, P=0.046), and higher interleukin-6 (IL-6) and lactate dehydrogenase (LDH) values as compared to survivors. In multivariable analysis, NIV duration ≥5 days on admission [odds ratio (OR): 42.20, 95% confidence interval (CI): 1.22 to >99, P=0.038] and IL-6 [OR: 4.08, 95% CI: 1.16-14.33, P=0.028] remained independently predictive of mortality. In worsening tertiles of partial pressure of oxygen (pO)/inspiratory oxygen fraction (FiO) on admission (≥161.5, 96.5 to <161.5, <96.5) we observed a stepwise increase in intubation rates (P=0.0034) and mortality rates (P=0.031).

CONCLUSIONS

As inflammation, ARDS severity and longer NIV duration prior to ICU are associated with intubation and mortality rates, prognosis appears to be largely determined by disease severity. Whether NIV aggravates ARDS or if it indicates lack of recovery independent from type of ventilation, or both should be clarified in a prospective trial.

摘要

背景

2019年冠状病毒病(COVID-19)患者在重症监护病房(ICU)接受治疗的临床结局仍然不容乐观。这项回顾性研究的目的是探索性地确定确诊为COVID-19的ICU患者不良结局的潜在预测因素。

方法

在我们ICU的所有COVID-19患者(n = 50)或合并严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)的患者(n = 11)中,我们评估了对结局可能有影响的临床、呼吸和实验室参数。主要结局变量是插管率和死亡率。

结果

2020年3月至2021年3月期间,573例患者因感染SARS-CoV-2住院。其中,61例(10.6%,女性占44.3%)年龄为66.4±13.3岁的患者被收入ICU。73.8%的患者患有中度或重度急性呼吸窘迫综合征(ARDS)。COVID-19患者与合并SARS-CoV-2的患者在临床上有所不同,例如严重的心衰或肾衰或脓毒症是入住ICU的主要原因,尽管死亡率相似(44.0%对45.5%,P>0.5)。在COVID-19患者中,死亡患者比存活患者更常出现严重ARDS(91%对46%,P = 0.001),在入住ICU前接受无创通气(NIV)治疗的时间更长(6.3±5.9天对2.5±2.0天,P = 0.046),并且白细胞介素-6(IL-6)和乳酸脱氢酶(LDH)值更高。在多变量分析中,入院时NIV持续时间≥5天[比值比(OR):42.20,95%置信区间(CI):1.22至>99,P = 0.038]和IL-6[OR:4.08,95%CI:1.16 - 14.33,P = 0.028]仍然是死亡率的独立预测因素。在入院时氧分压(pO)/吸入氧分数(FiO)的恶化三分位数(≥161.5、96.5至<161.5、<96.5)中,我们观察到插管率(P = 0.0034)和死亡率(P = 0.031)呈逐步上升。

结论

由于炎症、ARDS严重程度以及入住ICU前较长的NIV持续时间与插管率和死亡率相关,预后似乎在很大程度上由疾病严重程度决定。NIV是加重了ARDS,还是表明无论通气类型如何都缺乏恢复,或者两者皆有,应在前瞻性试验中加以阐明。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf86/9186226/0aafa557283b/jtd-14-05-1319-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验